![](https://s3.amazonaws.com/cache.altmetric.com/policy/thumbnails/thumbnail-20b5d7b6e7ef02c3b87ddd178f6018e76914c643f363442c7b5983e73c8efe61.jpg)
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
Cited by Canadian Agency for Drugs and Technologies in Health on
CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.